{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:51:58Z","timestamp":1793479918697,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anhedonia is a core feature of major depressive disorder (MDD), yet the clinical burden in real-world settings is not well understood. This retrospective cohort study assessed depression symptoms and treatment patterns among patients with MDD with and without prominent anhedonia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with MDD were selected from a real-world dataset of electronic health records from mental health specialists and linked medical and pharmacy claims (OM1, Inc. Boston MA) between January 2013 through August 2023. Patients were included if the first Patient Health Questionnaire 9-item (PHQ-9) score indicated moderate to severe depression (\u2265\u200910) with a MDD diagnosis +\/-30 days. The date of the patients\u2019 first PHQ-9 score was used as the index date. Patients with a score\u2009\u2265\u20092 on PHQ-9 item 1 (anhedonia) at the index date were classified as MDD with prominent anhedonia (MDD-ANH) (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094,255). The remaining patients were classified as Other-MDD (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091,454). Treatment patterns were assessed using prescription records in the year following the index date. The last PHQ-9 score in the year following the index date was used to assess remission rates (PHQ-9 score\u2009&lt;\u20095) or persistence of moderate to severe depression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 5,709 patients with MDD were assessed; 74.5% were in MDD-ANH and 25.5% were in the Other-MDD cohort (met criteria for MDD but not prominent anhedonia). The mean index PHQ-9 score was 18.2 (SD\u2009=\u20094.2) for MDD-ANH patients and 13.5 (SD\u2009=\u20092.9) for Other-MDD patients. The percentage of patients treated with antidepressants was 86.4% in the MDD-ANH group and 84.7% in the Other-MDD group. After adjusting for baseline characteristics, patients with MDD-ANH were more likely to have been treated with atypical antipsychotics (OR\u2009=\u20091.51,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), more likely to have switched medication (OR\u2009=\u20091.24,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), and more likely to have augmented antidepressant therapy (OR\u2009=\u20091.16,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021) than Other-MDD patients. Patients with MDD-ANH were less likely to have achieved remission (OR\u2009=\u20090.82,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003) and were more likely to have persistent depression (OR\u2009=\u20091.50,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) than patients with Other-MDD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, MDD-ANH patients had higher clinical burden reflected in more depressive symptoms, higher treatment utilization and lower rates of remission compared to Other-MDD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-025-07139-x","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:17:15Z","timestamp":1753438635000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical burden of major depressive disorder with versus without prominent anhedonia using a real-world electronic health records and claims linked database"],"prefix":"10.1186","volume":"25","author":[{"given":"Hrishikesh","family":"Kale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevan Geoffrey","family":"Severtson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becca S.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiina","family":"Drissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjana","family":"Dwibedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D.","family":"Marci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"4","key":"7139_CR1","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","volume":"75","author":"DS Hasin","year":"2018","unstructured":"Hasin DS, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the united States. JAMA Psychiatry. 2018;75(4):336\u201346.","journal-title":"JAMA Psychiatry"},{"key":"7139_CR2","unstructured":"Diagnostic. and Statistical Manual of Mental Disorders. 5th ed., text rev.; DSM-5-TR; American Psychiatric Association, 2022."},{"issue":"12","key":"7139_CR3","doi-asserted-by":"publisher","first-page":"pyae055","DOI":"10.1093\/ijnp\/pyae055","volume":"27","author":"A Luca","year":"2024","unstructured":"Luca A, Luca M, Kasper S, Pecorino B, Zohar J, Souery D, Montgomery S, Ferentinos P, Rujescu D, Messina A, Zanardi R, Ferri R, Tripodi M, Baune BT, Fanelli G, Fabbri C, Mendlewicz J, Serretti A. Anhedonia is associated with a specific depression profile and poor antidepressant response. Int J Neuropsychopharmacol. 2024;27(12):pyae055. https:\/\/doi.org\/10.1093\/ijnp\/pyae055. PMID: 39521954; PMCID: PMC11630035.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"7139_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jaac.2012.01.011","volume":"51","author":"DL McMakin","year":"2012","unstructured":"McMakin DL, Olino TM, Porta G, Dietz LJ, Emslie G, Clarke G, Wagner KD, Asarnow JR, Ryan ND, Birmaher B, Shamseddeen W, Mayes T, Kennard B, Spirito A, Keller M, Lynch FL, Dickerson JF, Brent DA. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J Am Acad Child Adolesc Psychiatry. 2012;51(4):404\u201311. Epub 2012 Mar 3. PMID: 22449646; PMCID: PMC3536476.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"7139_CR5","doi-asserted-by":"publisher","first-page":"20m13699","DOI":"10.4088\/JCP.20m13699","volume":"82","author":"M Zhdanava","year":"2021","unstructured":"Zhdanava M, Pilon D, Ghelerter I, et al. The prevalence and National burden of treatment-resistant depression and major depressive disorder in the united States. J Clin Psychiatry. 2021;82(2):20m13699.","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"7139_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.18553\/jmcp.2019.25.7.823","volume":"25","author":"M Sussman","year":"2019","unstructured":"Sussman M, O\u2019sullivan AK, Shah A, Olfson M, Menzin J. Economic burden of Treatment-Resistant depression on the U.S. Health care system. J Manag Care Spec Pharm. 2019;25(7):823\u201335. https:\/\/doi.org\/10.18553\/jmcp.2019.25.7.823. PMID: 31232205; PMCID: PMC10398213.","journal-title":"J Manag Care Spec Pharm"},{"key":"7139_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fpsyt.2019.00017","volume":"10","author":"B Cao","year":"2019","unstructured":"Cao B, et al. The efficacy of Vortioxetine on anhedonia in patients with major depressive disorder. Front Psychiatry. 2019;10:17.","journal-title":"Front Psychiatry"},{"key":"7139_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1744-859X-8-22","volume":"8","author":"L Pelizza","year":"2009","unstructured":"Pelizza L, Ferrari A. Anhedonia in schizophrenia and major depression: state or trait? Ann Gen Psychiatry. 2009;8:22. https:\/\/doi.org\/10.1186\/1744-859X-8-22. PMID: 19811665; PMCID: PMC2764701.","journal-title":"Ann Gen Psychiatry"},{"key":"7139_CR9","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jad.2024.04.086","volume":"356","author":"S Wong","year":"2024","unstructured":"Wong S, Le GH, Phan L, Rhee TG, Ho R, Meshkat S, Teopiz KM, Kwan ATH, Mansur RB, Rosenblat JD, McIntyre RS. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis. J Affect Disord. 2024;356:684\u201398. Epub 2024 Apr 23. PMID: 38657767.","journal-title":"J Affect Disord"},{"issue":"3","key":"7139_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1089\/cap.2014.0105","volume":"25","author":"V Gabbay","year":"2015","unstructured":"Gabbay V, Johnson AR, Alonso CM, Evans LK, Babb JS, Klein RG. Anhedonia, but not irritability, is associated with illness severity outcomes in adolescent major depression. J Child Adolesc Psychopharmacol. 2015;25(3):194\u2013200. https:\/\/doi.org\/10.1089\/cap.2014.0105. Epub 2015 Mar 24. PMID: 25802984; PMCID: PMC4403015.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"7139_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.comppsych.2018.09.006","volume":"87","author":"M Zimmerman","year":"2018","unstructured":"Zimmerman M, Balling C, Chelminski I, Dalrymple K. Understanding the severity of depression: Which symptoms of depression are the best indicators of depression severity? Compr Psychiatry. 2018;87:84\u20138. https:\/\/doi.org\/10.1016\/j.comppsych.2018.09.006. Epub 2018 Sep 24 PMID: 30282058.","journal-title":"Compr Psychiatry."},{"issue":"11","key":"7139_CR12","doi-asserted-by":"publisher","first-page":"e1480","DOI":"10.4088\/JCP.13097TX1C","volume":"76","author":"AA Nierenberg","year":"2015","unstructured":"Nierenberg AA. Residual symptoms in depression: prevalence and impact. J Clin Psychiatry. 2015;76(11):e1480. https:\/\/doi.org\/10.4088\/JCP.13097TX1C.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"7139_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.9758\/cpn.23.1086","volume":"21","author":"A Serretti","year":"2023","unstructured":"Serretti A. Anhedonia and depressive disorders. Clin Psychopharmacol Neurosci. 2023;21(3):401\u20139. https:\/\/doi.org\/10.9758\/cpn.23.1086. PMID: 37424409; PMCID: PMC10335915.","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"5","key":"7139_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/da.22709","volume":"35","author":"D Ducasse","year":"2018","unstructured":"Ducasse D, Loas G, Dassa D, Gramaglia C, Zeppegno P, Guillaume S, Oli\u00e9 E, Courtet P. Anhedonia is associated with suicidal ideation independently of depression: A meta-analysis. Depress Anxiety. 2018;35(5):382\u201392. https:\/\/doi.org\/10.1002\/da.22709. Epub 2017 Dec 12. PMID: 29232491.","journal-title":"Depress Anxiety"},{"issue":"18","key":"7139_CR15","first-page":"1737","volume":"282","author":"RL Spitzer","year":"1999","unstructured":"Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient Health Questionnaire JAMA. 1999;282(18):1737\u201344.","journal-title":"Patient Health Questionnaire JAMA"},{"issue":"9","key":"7139_CR16","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"7139_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613\u20139. https:\/\/doi.org\/10.1016\/0895-4356(92)90133-8. PMID: 1607900.","journal-title":"J Clin Epidemiol."},{"issue":"11","key":"7139_CR18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83. PMID: 16224307.","journal-title":"Med Care."},{"issue":"2","key":"7139_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4088\/JCP.16m10641","volume":"78","author":"M Zimmerman","year":"2017","unstructured":"Zimmerman M, Walsh E, Friedman M, Boerescu DA, Attiullah N. Identifying Remission From Depression on 3 Self-Report Scales. J Clin Psychiatry. 2017;78(2):177\u201383. https:\/\/doi.org\/10.4088\/JCP.16m10641. PMID: 28234434.","journal-title":"J Clin Psychiatry."},{"issue":"8","key":"7139_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40263-023-01026-3","volume":"37","author":"M Castro","year":"2023","unstructured":"Castro M, Wilkinson ST, Al Jurdi RK, Petrillo MP, Zaki N, Borentain S, Fu DJ, Turkoz I, Sun L, Brown B, Cabrera P. Efficacy and safety of Esketamine nasal spray in patients with Treatment-Resistant depression who completed a second induction period: analysis of the ongoing SUSTAIN-3 study. CNS Drugs. 2023;37(8):715\u201323. https:\/\/doi.org\/10.1007\/s40263-023-01026-3. Epub 2023 Aug 9. PMID: 37558912; PMCID: PMC10439056.","journal-title":"CNS Drugs"},{"issue":"4","key":"7139_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1176\/appi.ps.201900295","volume":"71","author":"RY Coley","year":"2020","unstructured":"Coley RY, Boggs JM, Beck A, Hartzler AL, Simon GE. Defining success in Measurement-Based care for depression: A comparison of common metrics. Psychiatr Serv. 2020;71(4):312\u20138. https:\/\/doi.org\/10.1176\/appi.ps.201900295. Epub 2019 Dec 18. PMID: 31847739.","journal-title":"Psychiatr Serv"},{"issue":"1\u20133","key":"7139_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jad.2006.08.020","volume":"99","author":"IH Franken","year":"2007","unstructured":"Franken IH, Rassin E, Muris P. The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton pleasure scale (SHAPS). J Affect Disord. 2007;99(1\u20133):83\u20139.","journal-title":"J Affect Disord"},{"issue":"1","key":"7139_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jad.2012.12.012","volume":"150","author":"J Wilkowska-Chmielewska","year":"2013","unstructured":"Wilkowska-Chmielewska J, Szelenberger W, Wojnar M. Age-dependent symptomatology of depression in hospitalized patients and its implications for DSM-5. J Affect Disord. 2013;150(1):142\u20135. https:\/\/doi.org\/10.1016\/j.jad.2012.12.012. Epub 2013 Jan 17. PMID: 23332650.","journal-title":"J Affect Disord"},{"key":"7139_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.neubiorev.2016.03.004","volume":"65","author":"SJ Rizvi","year":"2016","unstructured":"Rizvi SJ, Pizzagalli DA, Sproule BA, Kennedy SH. Assessing anhedonia in depression: potentials and pitfalls. Neurosci Biobehav Rev. 2016;65:21\u201335. https:\/\/doi.org\/10.1016\/j.neubiorev.2016.03.004. Epub 2016 Mar 6. PMID: 26959336; PMCID: PMC4856554.","journal-title":"Neurosci Biobehav Rev"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07139-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-07139-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07139-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:09:35Z","timestamp":1781604575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-025-07139-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7139"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-07139-x","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol for the database was reviewed by Advarra IRB (IRB#00000971). The IRB determined this research project to be exempt. This study adhered to the tenets of the Declaration of Helsinki.\u00a0The database used for this study is fully de-identified and compliant with the Health Insurance Portability and Accountability Act (HIPAA). A description of the database was submitted and determined to be exempt by Advarra CIRBI. This study involved retrospective, observational real-world data that is de-identified\/anonymized; obtaining informed consent from individual patients is not required. This study was conducted in compliance with the US FDA Title 21 Code of Federal Regulations (CFR) Part 50 \u2013 Protection of Human Patients and Part 56 \u2013 Institutional Review Boards; the International Council for Harmonisation for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines E6R2 (November 09, 2016) as they apply to post-marketing, observational studies; the Guidelines for Good Pharmacoepidemiology Practices (GPP) issued by the International Society for Pharmacoepidemiology (ISPE); the Belmont Report; US Title 45 CFR Part 164 Subpart E \u2013 Privacy of Individually Identifiable Health Information and the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy Rule (2002). This study adhered to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was supported by Johnson & Johnson. Hrishikesh Kale, Tiina Drissen, and Nilanjana Dwibedi are employees of Johnson & Johnson.Andrew J Cutler is a consultant for Johnson & Johnson.Stevan Geoffrey Severtson, Becca S Feldman and Carl D Marci are employees of OM1 which received funding from Johnson & Johnson to conduct this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"727"}}